Literature DB >> 3181286

Use of a pharmacological indicator to monitor compliance with thyroxine.

N D Penn1, S Peaker, A P Griffiths, M Feely, H Tindall.   

Abstract

Poor compliance with medication is often suspected, but difficult to confirm. The compliance of fourteen newly diagnosed hypothyroid patients was assessed using both TSH levels and low-dose phenobarbitone as a pharmacological marker. The study confirms the value of phenobarbitone as an indicator of compliance over a protracted period and suggests that it could be used to differentiate under-treatment from poor compliance.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3181286     DOI: 10.1007/bf00558274

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Analysis of barbiturates in blood by high-performance liquid chromatography.

Authors:  R Gill; A A Lopes; A C Moffat
Journal:  J Chromatogr       Date:  1981-11-13

2.  The spectrum of thyroid disease in a community: the Whickham survey.

Authors:  W M Tunbridge; D C Evered; R Hall; D Appleton; M Brewis; F Clark; J G Evans; E Young; T Bird; P A Smith
Journal:  Clin Endocrinol (Oxf)       Date:  1977-12       Impact factor: 3.478

3.  Low-dose phenobarbitone as an indicator of compliance with drug therapy.

Authors:  M Feely; J Cooke; D Price; S Singleton; A Mehta; L Bradford; R Calvert
Journal:  Br J Clin Pharmacol       Date:  1987-07       Impact factor: 4.335

4.  The effect of low-dose phenobarbitone on three indices of hepatic microsomal enzyme induction.

Authors:  D E Price; A Mehta; B K Park; A Hay; M P Feely
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

  4 in total
  4 in total

1.  Measurement of patient compliance and the interpretation of randomized clinical trials.

Authors:  R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The prediction of steady-state plasma phenobarbitone concentrations (following low-dose phenobarbitone) to refine its use as an indicator of compliance.

Authors:  T Pullar; S Kumar; H Chrystyn; P Rice; S Peaker; M Feely
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

3.  Initial evaluation of low-dose phenobarbital as an indicator of compliance with antimalarial drug treatment.

Authors:  J Karbwang; W Fungladda; C E Pickard; S Shires; A Hay; M Feely
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

Review 4.  Role of patient compliance in clinical pharmacokinetics. A review of recent research.

Authors:  J Urquhart
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.